Beta Bionics, Inc. · NASDAQ (us_market)
Healthcare · Medical Devices · United States
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-08$31.99 RISE2026-05-14$9.20 PEAK2026-05-29$12.12 141d | -71.2% 126d | Missed | Missed | — | — | +31.7% 15d | Missed |
DROP2026-01-08$31.99 RISE2026-04-10$8.86 PEAK2026-04-15$13.02 97d | -72.3% 92d | Missed | Missed | — | — | +47.0% 5d | Missed |
DROP2025-06-05$19.55 RISE2025-07-15$12.53 PEAK2025-09-12$26.41 99d | -35.9% 40d | Missed | Missed | — | — | +110.8% 59d | Missed |
DROP2025-01-31$23.81 RISE2025-04-08$9.71 PEAK2025-06-05$19.55 125d | -59.2% 67d | Missed | Missed | — | — | +101.3% 58d | Missed |
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $19 to $17.
The device called Mint, which would work with the company’s adaptive insulin dosing algorithm, is expected to debut in the first half of 2027.
The device called Mint, which would work with the company’s adaptive insulin dosing algorithm, is expected to debut in the first half of 2027.
IRVINE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end of the second quarter of 2027, subject to regulatory clearance by the U.S. Food and Drug Administration (FDA). The updated Mint commercialization timeline expectation is based on the FDA’s initial responses to the company’s Mint alternate controller enabled (ACE)
Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it expects to fully commercialize Mint by the end of the second quarter of 2027,
B of A Securities analyst Travis Steed maintains Beta Bionics (NASDAQ:BBNX) with a Neutral and lowers the price target from $23 to $11.
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.
Exploring the Latest 13F Filing and Investment Strategies
International expansion and Omnipod 6 development support the long-term growth narrative for Insulet. Read more on why this stock could be a value play for investors.
Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company’s iLet insulin pump platform. Speaking at a Bank of
Beta Bionics, Inc. (BBNX) Bank of America Global Healthcare Conference 2026 May 12, 2026 2:20 PM EDTCompany ParticipantsStephen Feider - CFO, Treasurer...
Presenter SpeechUnknown Analyst Next up, we have Beta Bionics, Stephen Feider, Chief Financial Officer; and we have Blake, Investor Relations. Right -- that's right. Great.QuestionUnknown Analyst
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Leading contributors in the Fund included Ultra Clean Holdings, Oil States International, Lincoln Educational Services, Advanced Energy and FormFactor.
IRVINE, Calif., April 27, 2026 -- Beta Bionics, Inc. , a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of...
Moby summary of Beta Bionics, Inc.'s Q1 2026 earnings call
Leerink Partners analyst Mike Kratky maintains Beta Bionics (NASDAQ:BBNX) with a Outperform and lowers the price target from $25 to $24.
Stifel analyst Jonathan Block maintains Beta Bionics (NASDAQ:BBNX) with a Buy and lowers the price target from $22 to $20.
Beta Bionics Inc (BBNX) reports a 57% increase in net sales and raises full-year guidance despite facing FDA challenges and competitive pressures.
Beta Bionics (NASDAQ:BBNX) reported first-quarter 2026 net sales of $27.6 million, up 57% year-over-year, as management cited growth in new patient starts, a rising base of recurring pharmacy users, and continued expansion of pharmacy channel access for its iLet insulin delivery system. Quarterly r
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BBNX | +17.78% | -3.19% | -60.22% | -29.70% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +14.82% | +2.52% | -56.78% | -42.39% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Citadel | multi-strat | 2.53M | $25.30M | 0.03% | Added+155.7% | 2026-03-31 |
| StateStreet | passive | 946.1K | $9.48M | 0.00% | Added+9.6% | 2026-03-31 |
| TwoSigma | quant | 65.5K | $656.26K | 0.00% | Trimmed-84.0% | 2026-03-31 |
| FidelityFMR | fundamental | 3.2K | $32.05K | 0.00% | Trimmed-81.3% | 2026-03-31 |
| TRowePrice | fundamental | 35.5K | $356 | 0.00% | Trimmed-93.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-21upcoming | -0.55 | — | — |
| 2026-04-21 | -0.45 | -0.36 | +21.06% |
| 2026-02-17 | -0.38 | -0.19 | +49.38% |
| 2025-10-28 | -0.41 | -0.33 | +19.84% |
| 2025-07-29 | -0.47 | -0.27 | +41.43% |
| 2025-05-06 | -0.51 | -0.93 | -83.79% |
| 2025-03-25 | -1.22 | -2.72 | -123.56% |